How to Apply
Faculty Mentors
Translational
- David M. Jablons, M.D.
- Laura J. Esserman, M.D., M.B.A.
- Michael J. Campbell, Ph.D.
- Kimberly Kirkwood, M.D.
- Jeroen Roose, PhD
- Christina Yau, PhD.
- Liang You, Ph.D.
- Julie Saba, MD, PhD
Regulatory Sciences
- Laura Van 'T Veer, PhD
- Kathy Giacomini, PhD
- Deanna Kroetz, PhD
- Barbara Koenig, PhD, RN
- Nola Hylton, PhD
- Brian Shoichet, PhD
- Ida Sim, MD, PhD
Health Services & Implementation Science
- Emily Finlayson, M.D., M.S.
- Elizabeth C. Wick, M.D.
- Julie Ann Sosa, M.D., M.A., FACS
- Louise Walter, MD
- Andrew Auerbach, MD
- Kim Rhoads, M.D., M.P.H
- Alex Smith, MD, MPH
- Maren Scheuner-Purcell, MD, MPH
- Leslie Wilson, PhD
Fellows
Current Fellows
- Nisha Parmeshwar, M.D.
- Alexis K. Colley, M.D., M.S.
- Nathan R. Brand, M.D.
- Kelli Ann Ifuku, M.D.
Past Fellows 2021-2022
- Laura L. Barnes, M.D.
- Nathan R. Brand, M.D.
- Patricia Conroy, M.D.
Past Fellows 2020-2021
- Alexa Glencer, M.D.
- Joseph Lin, M.D.
Curriculum
Trainee Portal
T32 Trainee Experiences
Deanna Kroetz, PhD
- Professor, Bioengineering and Therapeutic Sciences
Education
Institution
Degree
Dept or School
End Date
Biography
The overarching goal of the Kroetz laboratory is to understand the molecular basis of interindividual variability in drug response and toxicity. Genomic association studies are used to identify genes and pathways involved in common toxicities associated with cancer therapy, including taxane-induced peripheral neuropathy and bevacizumab-induced hypertension. Functional genomic studies are then used to define the role of these genes and pathways in the dose-limiting toxicities. A second area of research is on the role of ABC transporters in drug resistance and physiologic function. Ongoing efforts include cryo-EM studies of MRP4 and investigation of MRP4 in resistance to immunotherapy.Awards & Honors
Award
Confired By
Date
Mentoring Overview
Dr. Kroetz is an internationally recognized pharmacologist with expertise in drug metabolism and transport, and pharmacogenomics. Her research program is focused on understanding host variability in drug response and toxicity, include the pharmacogenomics of cancer treatment related toxicities, efflux transporter structure and function, and regulatory science. Dr. Kroetz just recently completed 10 years as the Director of the Pharmaceutical Sciences and Pharmacogenomics (PSPG) Graduate Program and PI of the associated T32. She has mentored 15 graduate students, 10 pharmaceutical sciences pathway students, and more than 20 postdocs and visiting faculty.
Trainee opportunities in Dr. Kroetz's lab range from participation in large clinical pharmacogenomics studies to iPSC-induced sensory neuron studies of gene function and drug toxicity, to collaborative studies to solve the structure of ABC transporters.
Research & Funding
Data provided by UCSF Profiles, powered by CTSI
ORCID iD: 0000-0001-5997-270X 
- Sphingolipid Signaling and Chemotherapy-Induced Peripheral NeurotoxicitySponsor: NIHSponsor ID: R01CA261068Funding Period:Apr 2021-Mar 2026Principal Investigator
- The Role of Genomics in Postoperative Delirium and SedationSponsor: NIH/NINRSponsor ID: R01 NR017622Funding Period:Oct 2019-Sep 2022Co-investigator leading the genomic analyses
- Developing Silastic-Silicone for the Local Delivery of Hormonal Therapy to Prevent and Treat Breast CancerSponsor: NIH/NCISponsor ID: R01 CA220131Funding Period:Jul 2017-Jun 2022Co-Investigator
- Pharmaceutical Sciences and PharmacogenomicsSponsor: NIH/NIGMSSponsor ID: T32 GM007175-41Funding Period:Jul 1982-Jun 2022Principal Investigator
- Pharmacogenomics of Microtubule Targeting AgentsSponsor: NIHSponsor ID: R01 CA192156-01A1Funding Period:Jul 2015-Jun 2021Principal Investigator
- Targeting MRP4-Mediated PGE2 Efflux to Improve Sensitivity to ImmunotherapySponsor: The Cancer LeagueSponsor ID: Cancer CenterFunding Period:Jun 2020-May 2021Principal Investigator
- Individualized Therapy for Recurrent GlioblastomaSponsor:Sponsor ID: Private FoundationFunding Period:Apr 2018-Mar 2021Co-investigator for pharmacology
Clinical Trials
Data provided by UCSF Profiles, powered by CTSI
- Study ID: NCT04534153Start Date: Oct 2022Estimated Completion Date: Mar 2023Condition(s): Impact of Excipients on Drug Absorption
- Study ID: NCT01497483Start Date: Dec 2011Estimated Completion Date: Dec 2013Condition(s):
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 131
Data provided by UCSF Profiles, powered by CTSI
- Siegel DA, Thanh C, Wan E, Hoh R, Hobbs K, Pan T, Gibson EA, Kroetz DL, Martin J, Hecht F, Pilcher C, Martin M, Carrington M, Pillai S, Busch MP, Stone M, Levy CN, Huang ML, Roychoudhury P, Hladik F, Jerome KR, Kiem HP, Henrich TJ, Deeks SG, Lee SA. Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size. AIDS. 2023 03 01; 37(3):477-488. View in PubMed
- Giacomini KM, Yee SW, Koleske ML, Zou L, Matsson P, Chen EC, Kroetz DL, Miller MA, Gozalpour E, Chu X. New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. Clin Pharmacol Ther. 2022 09; 112(3):540-561. View in PubMed
- Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan; 126(1):162. View in PubMed
- Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274. View in PubMed
- Bajaj R, Chong LB, Zou L, Tsakalozou E, Ni Z, Giacomini KM, Kroetz DL. Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. AAPS J. 2021 09 15; 23(5):106. View in PubMed
- View All Publications